STOCK TITAN
  1. Home
  2. News
  3. VNDA

Vanda Pharmaceuticals Inc - VNDA STOCK NEWS

Welcome to our dedicated news page for Vanda Pharmaceuticals (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vanda Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vanda Pharmaceuticals's position in the market.

News
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
Rhea-AI Summary
Vanda Pharmaceuticals Inc. announced the adoption of a duration stockholder rights plan to protect stockholder interests and maximize value. The plan was in response to an unsolicited acquisition proposal and aims to prevent any entity from gaining control without paying a premium. The plan will be in effect for one year, with the possibility of early termination.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
Rhea-AI Summary
Vanda Pharmaceuticals rejects unsolicited takeover proposals from Future Pak, determining they undervalue the company. The most recent offer was $7.25 - $7.75 per share. Shareholders are advised no action is required at this time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
Rhea-AI Summary
Future Pak, a WIXOM-based company, has proposed to acquire Vanda Pharmaceuticals for $7.25 to $7.75 per share in cash, representing a premium of 79.0% to 91.4% over Vanda's closing price. Future Pak aims to engage in good faith negotiations with Vanda to potentially increase the offer value. The proposal does not include a financing contingency, and Future Pak has the support of Colbeck Capital Management. Despite multiple attempts, Vanda has not responded to previous proposals offering significant premiums.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
News
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Rhea-AI Summary
Vanda Pharmaceuticals' Fanapt® Receives FDA Approval for Bipolar I Disorder Treatment, Expanding Commercial Opportunities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.16%
Tags
fda approval
-
News
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
Rhea-AI Summary
Vanda Pharmaceuticals Inc. received a Complete Response Letter (CRL) from the FDA regarding its supplemental New Drug Application (sNDA) for HETLIOZ® in treating insomnia. The FDA identified deficiencies, leading to the rejection of the sNDA in its current form.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
-
News
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) announced financial and operational results for the fourth quarter and full year ended December 31, 2023. Despite significant challenges, they supported their commercial programs and added PONVORY® to their portfolio alongside Fanapt® and HETLIOZ®. They advanced their clinical development pipeline with three NDA and sNDA submissions for insomnia, bipolar disorder, and gastroparesis, and are committed to advancing their clinical development pipeline and strengthening their commercial presence with innovative products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.81%
Tags
earnings
News
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
Rhea-AI Summary
Vanda Pharmaceuticals Inc. received a notification from the FDA regarding the ongoing review of its supplemental New Drug Application for HETLIOZ. The FDA identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. Vanda believes that the timing of the FDA's communication is part of an ongoing violation of the FDCA. The company is also challenging the FDA's approvals of several generic versions of HETLIOZ, which have been marketed since 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
News
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) will release its Q4 and full year 2023 results on February 7, 2024. The company will host a conference call to discuss the financial results and corporate activities. Investors can participate via phone or webcast, with a replay available until February 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
earnings
-
News
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) has received FDA approval for the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis, a common fungal infection of nails. VTR-297 is a small molecule histone deacetylase (HDAC) inhibitor, and the new treatment is a significant milestone in developing potential therapies for this disorder. The current therapies for onychomycosis include topical agents JUBLIA® (efinaconzole), KERYDIN® (tavaborole), and PENLAC® (ciclopirox). This is the first FDA approval for a new onychomycosis treatment since 2014.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
fda approval
News
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) won a motion for summary judgment against the FDA for unlawfully delaying the approval of HETLIOZ® to treat jet lag disorder. The court ordered the FDA to resolve the sNDA or commence a hearing by March 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
none
Stock VNDA logo
Vanda Pharmaceuticals Inc

Nasdaq:VNDA

VNDA Rankings

#3440 Ranked by Market Cap
#4919 Ranked by Stock Gains
N/A Ranked by Dividends

VNDA Stock Data

237.05M
52.05M
5.21%
91.5%
4.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Washington

About VNDA

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.